Iraqi registry data proves safety and efficacy of switching to adalimumab biosimilar in treating rheumatoid arthritis

HIGHLIGHTS

• What: The response in this study is lower compared to the overall change in disease activity because, despite the mean disease activity dropped from high to moderate, none of the participants reached remission or low disease activity by the end of the study period. While none of the patients in this study reached a complete response, this could be attributable to the patients` prior therapies where the majority of the participants in the current study had prior bDMARDs use (70.1%) .
• Who: User from the Department of Internal Medicine, Al-Nahrain University, College of Medicine . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.